
Natural Plasma Nano-EVs for Drug DeliveryAward last edited on: 2/19/2024
Sponsored Program
SBIRAwarding Agency
NIH : NIGMSTotal Award Amount
$275,389Award Phase
1Solicitation Topic Code
859Principal Investigator
Ajay VermaCompany Information
Phase I
Contract Number: 1R43GM150371-01Start Date: 9/15/2023 Completed: 3/14/2024
Phase I year
2023Phase I Amount
$275,389Public Health Relevance Statement:
NARRATIVE Extracellular vesicles (EVs) are membrane-bound nanoparticles released by all cell types that transfer proteins and RNA between cells and tissues; however, most attempts to implement EVs for drug delivery utilized production in cell culture and show no significant improvement over artificial liposomes, likely due to low representation of EV subpopulation suitable for long-range transport. Here we propose drug delivery using plasma EVs, specifically a newly identified smaller plasma nanoEVs, which offer potential advantages due to improved safety, biodistribution and potential brain penetration.
Project Terms:
Blood; Blood Reticuloendothelial System; Bone Marrow; Bone Marrow Reticuloendothelial System; Brain; Brain Nervous System; Encephalon; Cell Culture Techniques; cell culture; cell cultures; Cell Line; CellLine; Strains Cell Lines; cultured cell line; Cells; Cell Body; Ion-Exchange Chromatography Procedure; Ion Exchange Chromatography; Communication; Drug Carriers; Pharmaceutical Preparations; Drugs; Medication; Pharmaceutic Preparations; drug/agent; Engineering; Half-Life; Human; Modern Man; Immunoassay; Lipids; Liposomes; Liposomal; Liver; hepatic body system; hepatic organ system; Methods; Drug Kinetics; Pharmacokinetics; Plasma; Blood Plasma; Plasma Serum; Reticuloendothelial System, Serum, Plasma; Blood Plasma Volume; Plasma Volume; Positron-Emission Tomography; PET; PET Scan; PET imaging; PETSCAN; PETT; Positron Emission Tomography Medical Imaging; Positron Emission Tomography Scan; Rad.-PET; positron emission tomographic (PET) imaging; positron emission tomographic imaging; positron emitting tomography; Production; Proteins; Research; RNA; Non-Polyadenylated RNA; RNA Gene Products; Ribonucleic Acid; Safety; Spleen; Spleen Reticuloendothelial System; Testing; Tissues; Body Tissues; Measures; Antisense Oligonucleotides; Anti-Sense Oligonucleotides; Antisense Agent; anti-sense agent; anti-sense oligo; antisense oligo; Drug Delivery; Drug Delivery Systems; customs; Custom; Organ; improved; Procedures; Surface; Clinical; Penetration; Phase; Tropism; Therapeutic; Intravenous; Autologous; cell type; experience; Membrane; membrane structure; cell immortalization; novel; Disease model; disorder model; Reporting; Property; RNA marker; Size Exclusion Chromatography; Molecular Sieve Chromatography; Molecular Interaction; Binding; Dose; Molecular Profiling; Molecular Fingerprinting; molecular profile; molecular signature; Reproducibility; in vivo; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Radiolabeled; radiolabeling; radiologically labeled; nano; human stem cells; immunogenicity; nano particle; nano-sized particle; nanosized particle; nanoparticle; Biodistribution; site targeted delivery; targeted delivery; scale up; fluorescent imaging; fluorescence imaging; multiomics; multiple omics; protein markers; protein biomarkers; extracellular vesicles; delivery vehicle; delivery vector; pharmacologic; Circulation; Diameter
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00